TY - JOUR
T1 - Plasticizer Interaction with the Heart
T2 - Chemicals Used in Plastic Medical Devices Can Interfere with Cardiac Electrophysiology
AU - Jaimes, Rafael
AU - McCullough, Damon
AU - Siegel, Bryan
AU - Swift, Luther
AU - McInerney, Daniel
AU - Hiebert, James
AU - Perez-Alday, Erick A.
AU - Trenor, Beatriz
AU - Sheng, Jiansong
AU - Saiz, Javier
AU - Tereshchenko, Larisa G.
AU - Posnack, Nikki Gillum
N1 - Funding Information:
This work was supported by the National Institutes of Health (R00ES023477 and R01HL139472 to Dr Posnack), Children's Research Institute and Children's National Heart Institute. We thank the generosity of the NVIDIA corporation for the graphics processing unit to perform image processing. This work was partially supported by the Direccion General de Politica Científica de la Generalitat Valenciana (PROMETEU2016/088) to J.S. and B.T.
Funding Information:
This work was supported by the National Institutes of Health (R00ES023477 and R01HL139472 to Dr Posnack), Children’s Research Institute and Children’s National Heart Institute. We thank the generosity of the NVIDIA corporation for the graphics processing unit to perform image processing. This work was partially supported by the Dirección General de Política Científica de la Generalitat Valenciana (PROMETEU2016/088) to J.S. and B.T.
Publisher Copyright:
© 2019 American Heart Association, Inc.
PY - 2019/7/1
Y1 - 2019/7/1
N2 - Background: Phthalates are used as plasticizers in the manufacturing of flexible, plastic medical products. Patients can be subjected to high phthalate exposure through contact with plastic medical devices. We aimed to investigate the cardiac safety and biocompatibility of mono-2-ethylhexyl phthalate (MEHP), a phthalate with documented exposure in intensive care patients. Methods: Optical mapping of transmembrane voltage and pacing studies were performed on isolated, Langendorff-perfused rat hearts to assess cardiac electrophysiology after MEHP exposure compared with controls. MEHP dose was chosen based on reported blood concentrations after an exchange transfusion procedure. Results: Thirty-minute exposure to MEHP increased the atrioventricular node (147 versus 107 ms) and ventricular (117 versus 77.5 ms) effective refractory periods, compared with controls. Optical mapping revealed prolonged action potential duration at slower pacing cycle lengths, akin to reverse use dependence. The plateau phase of the action potential duration restitution curve steepened and became monophasic in MEHP-exposed hearts (0.18 versus 0.06 slope). Action potential duration lengthening occurred during late-phase repolarization resulting in triangulation (70.3 versus 56.6 ms). MEHP exposure also slowed epicardial conduction velocity (35 versus 60 cm/s), which may be partly explained by inhibition of Nav1.5 (874 and 231 μmol/L half-maximal inhibitory concentration, fast and late sodium current). Conclusions: This study highlights the impact of acute MEHP exposure, using a clinically relevant dose, on cardiac electrophysiology in the intact heart. Heightened clinical exposure to plasticized medical products may have cardiac safety implications - given that action potential triangulation and electrical restitution modifications are a risk factor for early after depolarizations and cardiac arrhythmias.
AB - Background: Phthalates are used as plasticizers in the manufacturing of flexible, plastic medical products. Patients can be subjected to high phthalate exposure through contact with plastic medical devices. We aimed to investigate the cardiac safety and biocompatibility of mono-2-ethylhexyl phthalate (MEHP), a phthalate with documented exposure in intensive care patients. Methods: Optical mapping of transmembrane voltage and pacing studies were performed on isolated, Langendorff-perfused rat hearts to assess cardiac electrophysiology after MEHP exposure compared with controls. MEHP dose was chosen based on reported blood concentrations after an exchange transfusion procedure. Results: Thirty-minute exposure to MEHP increased the atrioventricular node (147 versus 107 ms) and ventricular (117 versus 77.5 ms) effective refractory periods, compared with controls. Optical mapping revealed prolonged action potential duration at slower pacing cycle lengths, akin to reverse use dependence. The plateau phase of the action potential duration restitution curve steepened and became monophasic in MEHP-exposed hearts (0.18 versus 0.06 slope). Action potential duration lengthening occurred during late-phase repolarization resulting in triangulation (70.3 versus 56.6 ms). MEHP exposure also slowed epicardial conduction velocity (35 versus 60 cm/s), which may be partly explained by inhibition of Nav1.5 (874 and 231 μmol/L half-maximal inhibitory concentration, fast and late sodium current). Conclusions: This study highlights the impact of acute MEHP exposure, using a clinically relevant dose, on cardiac electrophysiology in the intact heart. Heightened clinical exposure to plasticized medical products may have cardiac safety implications - given that action potential triangulation and electrical restitution modifications are a risk factor for early after depolarizations and cardiac arrhythmias.
KW - action potentials
KW - electrophysiology
KW - heart
KW - plasticizer
KW - plastics
UR - http://www.scopus.com/inward/record.url?scp=85068958340&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068958340&partnerID=8YFLogxK
U2 - 10.1161/CIRCEP.119.007294
DO - 10.1161/CIRCEP.119.007294
M3 - Article
C2 - 31248280
AN - SCOPUS:85068958340
SN - 1941-3149
VL - 12
JO - Circulation: Arrhythmia and Electrophysiology
JF - Circulation: Arrhythmia and Electrophysiology
IS - 7
M1 - e007294
ER -